# Immuneering Corporation (IMRX): MoatMap facts

As of 14 Oct 2026. Research data, not investment advice.

As of 14 Oct 2026, MoatMap's StockRank for Immuneering Corporation (IMRX) is 18/100, ranked against 24,000+ stocks in 35 markets (Quality 37, Value 33, Momentum 29, each scored against its sector).

- StockRank: 18/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 37, Value 33, Momentum 29: each a 0-100 percentile within the stock's sector.
- Position: #22,098 overall, #1,985 in Healthcare.
- Listing: United States, NGM; Healthcare / Biotechnology.
- Last close: 3.86 USD on 12 Oct 2026.
- Insider filings, last 180 days: directors bought USD 36K.

Source: https://moatmap.ai/stock/IMRX
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker